Do you want to read an article? Please log in or register.
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
Migraine and Headache
RECOMMENDED
Related content
Migraine and Headache
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Headache
Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD
doi: 10.1111/head.14138
RECOMMENDED
Migraine and Headache
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Neurology.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK
doi: 10.1212/WNL.
Migraine and Headache
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
Headache
Kudrow D, Andrews JS, Rettiganti M, Oakes T, Bardos J, Gaul C, Riesenberg R, Wenzel R, Kuruppu D, Martinez J
doi: 10.1111/head.14011
RECOMMENDED
Migraine and Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM
doi: 10.1111/head.13970
Migraine and Headache
Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies
Headache.
Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C
doi: 10.1111/head.13636.
RECOMMENDED
Anxiety and DepressionBipolar Disorder
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
Am J Psychiatry.
Earley W, Victoria Burgess M, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN
doi: 10.1176/appi.ajp.
Migraine and Headache
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial
Lancet Neurol
Wilbrink LA, de Coo IF, Doesborg PGG, Mulleners WM, Teernstra OPM, Bartels EC, Burger K, Wille F, van Dongen RTM, Kurt E, Spincemaille GH, Haan J, van Zwet EW, Huygen FJPM, Ferrari MD, ICON study group.
doi: 10.1016/S1474-4422(21)00101-0
Migraine and Headache
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Cephalalgia
Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM
doi: 10.1177/0333102420966658
Migraine and Headache
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Lancet Neurol.
Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC
doi: 10.1016/S1474-4422(20)30279-9.